

In the Specification

Page 1, first paragraph, please amend as follows:

Technical Field

~~The present invention~~ This disclosure relates to a therapeutic or prophylactic agent for urinary frequency or urinary incontinence, and to a morphinan derivative having a nitrogen-containing hetrocyclic group or a pharmaceutically acceptable acid addition salt thereof.

Page 1, second paragraph, please amend as follows:

Background Art

Recently, with coming of an aging society, the number of patients suffering from urinary frequency or urinary incontinence is increasing year by year. At present, as therapeutic drugs for urinary frequency or urinary incontinence, anticholinergic drugs such as propiverine hydrochloride, oxybutynin hydrochloride and flavoxate hydrochloride are used. However, it has been reported that these existing drugs have side effects, that is, dry mouth, gastrointestinal system symptoms such as constipation, cardiovascular symptoms such as orthostatic hypotension, urinary retention and residual urine. In addition, it is concerned that by administering the existing drugs having anticholinergic activities for the therapy of urinary frequency or urinary incontinence accompanied by cerebrovascular dysfunction or dementia, cholinergic system activity in the brain is inhibited, so that the cerebrovascular dysfunction or dementia *per se* progress. On the other hand, from the view point of improving quality of life (QOL) of patients, which is recently regarded as important, urinary frequency and urinary incontinence are attracting attention as symptoms which should be positively cured. Thus, development of a therapeutic or prophylactic agent for urinary frequency or urinary incontinence without side effects is strongly demanded.

Page 2, first paragraph, please amend as follows:

Disclosure of the Invention Summary


~~An object of the present invention is to~~ We provide a novel therapeutic or prophylactic agent for urinary frequency or urinary incontinence, which has a high therapeutic or prophylactic effect and of which side effects are improved, as well as to provide a method for therapy or prophylaxis of the disease, use for the disease, and a novel compound useful for therapy or prophylaxis of the disease.

Page 2, second paragraph, please amend as follows:

~~To attain the above described object, the present inventors intensively studied to discover novel morphinan derivatives having a nitrogen-containing heterocyclic group, and that any of them including these morphinan derivatives has unexpectedly high therapeutic or prophylactic effect for urinary frequency or urinary incontinence, may be orally administered, which is advantageous for long term administration, and is free from the side effects such as drug dependence and constipation, thereby completing the present invention.~~

Page 2, third paragraph bridging pages 3 and 4, please amend as follows:

~~That is, the present invention provides~~ We provide a therapeutic or prophylactic agent for urinary frequency or urinary incontinence, comprising as an effective ingredient a morphinan derivative having a nitrogen-containing heterocyclic group of the Formula (I):



(I)


[wherein R¹ is hydrogen, C₁-C₅ alkyl, C₄-C₇ cycloalkenylalkyl, C₆-C₈ cycloalkenylalkyl, C₆-C₁₂ aryl, C₇-C₁₃ aralkyl, C₃-C₇ alkenyl, furanylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5), thienylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5) or pyridylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5), R² and R³ independently are hydrogen, hydroxy, C₁-C₅ alkoxy, C₃-C₇ alkenyloxy, C₇-C₁₃ aralkyloxy or C₁-C₅ alkanoyloxy; Y and Z independently represent valence bond or -C(=O)-; -X- represents a C₂-C₇ carbon chain (one or more of the carbon atoms therein may be ~~substituted~~ replaced by nitrogen, oxygen or sulfur atom(s), and the carbon chain may contain an unsaturated bond) constituting a part of the ring structure, k is an integer of 0 to 8; R⁴ is(are) (a) substituent(s) in the number of k on the nitrogen-containing ring, which independently represent(s) fluorine, chlorine, bromine, iodine, nitro, hydroxy, C₁-C₅ alkyl, C₇-C₁₃ cycloalkylalkyl, C₆-C₁₂ aryl, C₇-C₁₃ aralkyl, C₇-C₁₃ aralkyloxy, C₁-C₅ alkoxy, trifluoromethyl, trifluoromethoxy, cyano, isothiocyanato, SR⁶, SOR⁶, SO₂R⁶, (CH₂)_pOR⁶, (CH₂)_pCOR⁶, (CH₂)_pCO₂R⁶, SO₂NR⁷R⁸, CONR⁷R⁸, (CH₂)_pNR⁷R⁸ or (CH₂)_pN(R⁷)COR⁸, or among the R⁴s in the number of k, two R⁴s bound to the same carbon atom or to the same sulfur atom cooperatively represent one oxygen atom to form carbonyl or sulfoxide, or two R⁴s bound to the same carbon atom cooperatively represent one sulfur atom to form thiocarbonyl, or four R⁴s bound to the same sulfur atom cooperatively represent two oxygen atoms to form sulfone, or among the R⁴s in the number of k, two R⁴s bound to adjacent carbon atoms, respectively, cooperatively form benzene fused ring, pyridine fused ring, naphthalene fused ring, cyclopropane fused ring, cyclobutane fused ring, cyclopentane fused ring, cyclopentene fused ring, cyclohexane fused ring, cyclohexene fused ring, cycloheptane fused ring or cycloheptene fused ring, each of said fused rings is non-substituted or substituted by 1 or more R⁵s, wherein R⁵(s) independently represent(s) fluorine, chlorine, bromine, iodine, nitro, hydroxy, C₁-C₅ alkyl, C₁-C₅ alkoxy, trifluoromethyl, trifluoromethoxy, cyano, C₆-C₁₂

aryl, isothiocyanato, SR^6 , SOR^6 , SO_2R^6 , $(\text{CH}_2)_p\text{OR}^6$, $(\text{CH}_2)_p\text{COR}^6$, $(\text{CH}_2)_p\text{CO}_2\text{R}^6$, $\text{SO}_2\text{NR}^7\text{R}^8$, CONR^7R^8 , $(\text{CH}_2)_p\text{NR}^7\text{R}^8$ or $(\text{CH}_2)_p\text{N}(\text{R}^7)\text{COR}^8$; R^9 is hydrogen, C_1 - C_5 alkyl, C_1 - C_5 alkenyl, C_7 - C_{13} aralkyl, C_1 - C_3 hydroxyalkyl, $(\text{CH}_2)_p\text{OR}^6$ or $(\text{CH}_2)_p\text{CO}_2\text{R}^6$; R^{10} and R^{11} are bound to form -O-, -S- or - CH_2 -, or R^{10} is hydrogen and R^{11} is hydrogen, hydroxy, C_1 - C_5 alkoxy or C_1 - C_5 alkanoyloxy; p is an integer of 0 to 5; R^6 is hydrogen, C_1 - C_5 alkyl, C_3 - C_7 alkenyl, C_6 - C_{12} aryl or C_7 - C_{13} aralkyl; and R^7 and R^8 independently are hydrogen, C_1 - C_5 alkyl or C_7 - C_{13} aralkyl]

or a pharmaceutically acceptable acid addition salt thereof, as well as a method for therapy or prophylaxis of the diseases, and uses thereof for the diseases.

Page 4, last paragraph bridging page 5, please amend as follows:

~~The present invention~~ We also provides provide a morphinan derivative having a nitrogen-containing heterocyclic group of the Formula (II):



[wherein R^1 , R^2 , R^3 , R^9 , R^{10} and R^{11} represent the same meanings as described above, $\text{R}^{4'}$, X' , Y' , Z' and k' represent the same meanings as said R^4 , X , Y , Z and k within the proviso that in cases where Y' and Z' are simultaneously valence bonds and X' is $-(\text{CH}_2)_4-$, $-(\text{CH}_2)_5-$ or $-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-$, k' must be not less than 1, in cases where Y' and Z' are simultaneously $-\text{C}(=\text{O})-$ and X' is a chain comprising two carbon atoms constituting the ring structure, k' must be not less than 1, and in

particular, in cases where $(R^{4'})_k$ is a benzene fused ring, the benzene ring must be substituted by the $R^5]$

or a pharmaceutically acceptable acid addition salt thereof, as well as a pharmaceutical or pharmaceutical composition containing the compound.

Page 5, first paragraph, please amend as follows:

~~Best Mode for Carrying Out the Invention~~ Detailed Description

~~In practicing the present invention, the~~ The compounds represented by Formula (I) are preferably used. Among the compounds of Formula (I), those having the following substituent groups are preferred. In the present specification, “therapeutic or prophylactic agent” includes not only those which are used for one of therapy and prophylaxis, but also those aiming at attaining both therapy and prophylaxis simultaneously.

Page 7, last paragraph bridging pages 8 and 9, please amend as follows:

On the other hand, in cases where both Y and Z are valence bonds, R^1 is preferably hydrogen, C_1 - C_5 aralkyl, furanylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5), thienylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5) or pyridylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5), more preferably hydrogen, methyl, ethyl, propyl, benzyl, phenethyl, phenylpropyl, 2- or 3-furanylmethyl, 2- or 3-furanylethyl, 2- or 3-furanylpropyl, 2- or 3-thiophenylmethyl, 2- or 3-thiophenylethyl, 2- or 3-thiophenylpropyl, 2-, 3- or 4-pyridinylmethyl, 2-, 3- or 4-pyridinylethyl, or 2-, 3- or 4-pyridinylpropyl. Among these, hydrogen, methyl, phenethyl, furanylethyl, thiophenylethyl and pyridinylethyl are especially preferred. R^2 is preferably hydrogen, hydroxy, C_1 - C_5 alkoxy, C_3 - C_7 alkenyloxy, C_7 - C_{13} aralkyloxy or C_1 - C_5 alkanoyloxy. Among these, hydrogen, hydroxy, methoxy, ethoxy, allyloxy, benzyloxy, acetoxy and propionyloxy are preferred, and hydrogen, hydroxy, methoxy and acetoxy are preferred.

R^3 is preferably hydrogen, hydroxy, C_{1-5} alkoxy, C_7-C_{13} aralkyloxy or C_1-C_5 alkanoyloxy, more preferably, hydrogen, hydroxy, methoxy, ethoxy, benzyloxy, acetoxy or propionyloxy. Among these, hydrogen hydroxy, methoxy and acetoxy are especially preferred. The “-X-” is preferably C_4-C_6 carbon chain constituting a part of the ring structure, or the above-mentioned carbon chain in which one or two carbon atoms is(are) ~~substituted~~ replaced by oxygen, sulfur or nitrogen atom(s). Among these, especially preferred are carbon chain having 5 carbon atoms constituting a part of the ring structure and the carbon chain just mentioned above in which one carbon atom is ~~substituted~~ replaced by oxygen, sulfur or nitrogen atom. The “k” is preferably an integer of 0 to 6. R^4 is preferably $CONR^7R^8$ (wherein R^7 and R^8 are independently hydrogen, methyl, ethyl, propyl or benzyl), or two R^4 s preferably bound to adjacent carbon atoms, respectively, cooperatively form benzene fused ring, pyridine fused ring, naphthalene fused ring, cyclopropane fused ring, cyclobutane fused ring, cyclopentane fused ring, cyclopentene fused ring, cyclohexane fused ring, cyclohexene fused ring, cycloheptane fused ring or cycloheptene fused ring, each of the fused rings is non-substituted or substituted by 1 or more, especially 1 to 4 R^5 s. R^4 is more preferably dimethylamide or diethylamide, or to form the benzene fused ring. Other R^4 (s) is(are) preferably and independently methyl, ethyl, propyl or benzyl, or two R^4 s bound to the same carbon atom preferably represent one oxygen atom to form carbonyl. Especially preferably, the carbon atom adjacent to the above-mentioned carbonyl group is ~~substituted~~ replaced by nitrogen atom to form amide bond. Although the benzene fused ring which is not substituted is also preferred, the substituent(s) R^5 (s) is(are) preferably and independently fluorine, chlorine, bromine, iodine, nitro, C_1-C_5 alkyl (especially methyl, ethyl or propyl), C_7-C_{13} aralkyl (especially benzyl), hydroxy, C_1-C_5 alkoxy (especially methoxy or ethoxy), trifluoromethyl, trifluoromethoxy, cyano, phenyl, isothiocyanato, SR^6 , SOR^6 , SO^2R^6 , $(CH_2)_pOR^6$, $(CH_2)_pCOR^6$, $(CH_2)_pCO_2R^6$, $SO_2NR^7R^8$, $CONR^7R^8$, $(CH_2)_pNR^7R^8$ or

$(CH_2)_pN(R^7)COR^8$ (wherein p is an integer of 0 to 5; R^6 is hydrogen, C_1 - C_5 alkyl (especially methyl, ethyl or propyl), C_3 - C_7 alkenyl or C_6 - C_{12} aryl (especially phenyl); R^7 and R^8 independently are hydrogen, C_1 - C_5 alkyl (especially methyl, ethyl or propyl), or C_7 - C_{13} aralkyl (especially benzyl)). The benzene fused ring is more preferably non-substituted, or substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, nitro, methyl, ethyl, propyl, benzyl, hydroxy, methoxy, trifluoromethyl, trifluoromethoxy, cyano, phenyl, hydroxymethyl, hydroxyethyl, isothiocyanato, mercapto, methylthio, methylsulfinyl, methylsulfonyl, methoxymethyl, ethoxymethyl, methoxyethyl, acetoxyl, phenyloxy, methoxycarbonyl, ethoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, sulfamoyl, dimethylsulfamoyl, dimethylcarbamoyl, dimethylamino, dimethylaminomethyl, dimethylaminoethyl and amino. R^9 is preferably hydrogen, C_1 - C_5 alkyl, allyl or benzyl, more preferably hydrogen or methyl. R^{10} and R^{11} are preferably bound to form -O-, or R^{10} is preferably hydrogen and R^{11} is preferably hydrogen, hydroxy or methoxy. Especially preferably, R^{10} and R^{11} are bound to form -O-.

Page 9, last paragraph, please amend as follows:

~~The present invention~~ We also provides provide the morphinan derivatives having a nitrogen-containing heterocyclic group represented by the above-described Formula (II) and pharmaceutically acid addition salts thereof.

Page 11, last paragraph bridging pages 12 and 13, please amend as follows:

On the other hand, in cases where both Y' and Z' are valence bonds, R^1 is preferably hydrogen C_1 - C_5 alkyl, C_7 - C_{13} aralkyl, furanylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5), thienylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5) or pyridylalkyl (wherein the number of carbon atoms in the alkyl moiety is 1 to 5), more preferably hydrogen, methyl, ethyl, propyl, benzyl, phenethyl, phenylpropyl, 2- or 3-furanylmethyl, 2- or 3-

furanylethyl, 2- or 3-furanylpropyl, 2- or 3-thiophenylmethyl, 2- or 3-thiophenylethyl, 2- or 3-thiophenylpropyl, 2-, 3- or 4-pyridinylmethyl, 2-, 3- or 4-pyridinylethyl, or 2-, 3- or 4-pyridinylpropyl. Among these, hydrogen, methyl, phenethyl, furanylethyl, thiophenylethyl and pyridinylethyl are especially preferred. R^2 is preferably hydrogen, hydroxy, C_1 - C_5 alkoxy, C_3 - C_7 alkenyloxy, C_7 - C_{13} aralkyloxy or C_1 - C_5 alkanoyloxy. Among these, hydrogen, hydroxy, methoxy, ethoxy, allyloxy, benzyloxy, acetoxy and propionoxy are preferred, and hydrogen, hydroxy, methoxy and acetoxy are preferred. R^3 is preferably hydrogen, hydroxy, C_1 - C_5 alkoxy, C_7 - C_{13} aralkyloxy or C_1 - C_5 alkanoyloxy, more preferably, hydrogen, hydroxy, methoxy, ethoxy, benzyloxy, acetoxy or propionoxy. Among these, hydrogen, hydroxy, methoxy and acetoxy are especially preferred. The “-X’-“ is preferably C_4 - C_6 carbon chain constituting a part of the ring structure, or the above-mentioned carbon chain in which one or two carbon atoms is(are) ~~substituted~~ replaced by oxygen, sulfur or nitrogen atom(s). Among these, especially preferred are carbon chain having 5 carbon atoms constituting a part of the ring structure and the carbon chain just mentioned above in which one carbon atom is ~~substituted~~ replaced by oxygen, sulfur or nitrogen atom. The k' is preferably an integer of 0 to 6. $R^{4'}$ is preferably $CONR^7R^8$ (wherein R^7 and R^8 are independently hydrogen, methyl, ethyl, propyl, or benzyl), or two $R^{4'}$ s preferably bound to adjacent carbon atoms, respectively, cooperatively form benzene fused ring, pyridine fused ring, naphthalene fused ring, cyclopropane fused ring, cyclobutane fused ring, cyclopentane fused ring, cyclopentene fused ring, cyclohexane fused ring, cyclohexene fused ring, cycloheptane fused ring or cycloheptene fused ring, each of the fused rings is non-substituted or substituted by 1 or more, especially 1 to 4 R^5 s. $R^{4'}$ is more preferably dimethylamide or diethylamide, or to form the benzene fused ring. Other $R^{4'}$ (s) is(are) preferably and independently methyl, ethyl, propyl or benzyl, or two $R^{4'}$ s bound to the same carbon atom preferably represent one oxygen atom to form carbonyl. Especially preferably, the


carbon atom adjacent to the above-mentioned carbonyl group is ~~substituted~~ replaced by nitrogen atom to form amide bond. Although the benzene fused ring which is not substituted is also preferred, the substituent(s) R^5 (s) is(are) preferably and independently fluorine, chlorine, bromine, iodine, nitro, C_1 - C_5 alkyl (especially methyl, ethyl or propyl), C_7 - C_{13} aralkyl (especially benzyl), hydroxy, C_1 - C_5 alkoxy (especially methoxy or ethoxy), trifluoromethyl, trifluoromethoxy, cyano, phenyl, isothiocyanato, SR^6 , SOR^6 , SO^2R^6 , $(CH_2)_pOR^6$, $(CH_2)_pCOR^6$, $(CH_2)_pCO_2R^6$, $SO_2NR^7R^8$, $CONR^7R^8$, $(CH_2)_pNR^7R^8$ or $(CH_2)_pN(R^7)COR^8$ (wherein p is an integer of 0 to 5; R^6 is hydrogen, C_1 - C_5 alkyl (especially methyl, ethyl or propyl), C_3 - C_7 alkenyl or C_6 - C_{12} aryl (especially phenyl); R^7 and R^8 independently are hydrogen, C_1 - C_5 alkyl (especially methyl, ethyl or propyl), or C_7 - C_{13} aralkyl (especially benzyl)). The benzene fused ring is more preferably non-substituted, or substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, nitro, methyl, ethyl, propyl, benzyl, hydroxy, methoxy, trifluoromethyl, trifluoromethoxy, cyano, phenyl, hydroxymethyl, hydroxyethyl, isothiocyanato, mercapto, methylthio, methylsulfinyl, methylsulfonyl, methoxymethyl, ethoxymethyl, methoxyethyl, acetoxy, phenoxy, methoxycarbonyl, ethoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, sulfamoyl, dimethylsulfamoyl, dimethylcarbamoyl, dimethylamino, dimethylaminomethyl, dimethylcaminoethyl and amino. R^9 is preferably hydrogen, C_1 - C_5 alkyl, allyl or benzyl, more preferably hydrogen or methyl. R^{10} and R^{11} are preferably bound to form -O-, or R^{10} is preferably hydrogen and R^{11} is preferably hydrogen, hydroxy or methoxy. Especially preferably R^{10} and R^{11} are bound to form -O-.

Page 14, second paragraph, please amend as follows:

However, ~~the present invention~~ this disclosure is not restricted to those described above.


Page 14, fourth paragraph bridging page 15, please amend as follows:

Among the compounds of the Formula (I) ~~according to the present invention~~, specific examples of those wherein -X- is a carbon chain having two carbon atoms constituting a part of the ring structure; Y and Z are -C(=O)- ; two R⁴s form benzene fused ring which is not substituted or substituted by one or more R⁵s; R⁹ is hydrogen; R¹⁰ and R¹¹ are bound to represent -O-, that is, those represented by the Formula (Ia) below are shown in Table 1. In the tables described below, CPM means cyclopropylmethyl, and the bond at 6-position is α or β .



Page 20, first paragraph, please amend as follows:


Among the compounds of the Formula (I) ~~according to the present invention~~, specific examples of those wherein -X- is a carbon chain having three carbon atoms constituting a part of the ring structure; Y is -C(=O)- and Z is valence bond; two R⁴s form benzene fused ring which is not substituted or substituted by one or more R⁵s; R⁹ is hydrogen; R¹⁰ and R¹¹ are bound to represent -O-, that is, those represented by the Formula (Ib) below are shown in Table 2.



(Ib)

Page 27, first paragraph, please amend as follows:


Among the compounds of the Formula (I) ~~according to the present invention~~, specific examples of those wherein -X- is a carbon chain (single bond or unsaturated bond) having two carbon atoms constituting a part of the ring structure; Y and Z are -C(=O)-; R⁹ is hydrogen; R¹⁰ and R¹¹ are bound to represent -O-, that is, those represented by the Formula (Ic) below are shown in Table 3.



(Ic)

Page 29, last paragraph bridging page 30, please amend as follows:


Among the compounds of the Formula (I) ~~according to the present invention~~, specific examples of those wherein -X- is a carbon chain having three carbon atoms constituting a part of the ring structure; Y is -C(=O)- and Z is valence bond; R⁹ is hydrogen; R¹⁰ and R¹¹ are bound to represent -O-, that is, those represented by the Formula (Id) below are shown in Table 4.



(Id)

Page 32, first paragraph, please amend as follows:

Among the compounds of the Formula (I) ~~according to the present invention~~, specific examples of those wherein $-X(R^4)_{k-2}-$ is $-A-$; Y and Z are valence bonds; two R^4 's form benzene fused ring which is not substituted or substituted by one or more R^5 's; R^9 is hydrogen; R^{10} and R^{11} are bound to represent $-O-$, that is, those represented by the Formula (Ie) below are shown in Table 5.



(Ie)

Page 51, first paragraph, please amend as follows:

The morphinan derivatives represented by the above-described Formula (I), having a nitrogen-containing hetrocyclic group used as the effective ingredient of the therapeutic or prophylactic agent for urinary frequency or urinary incontinence ~~according to the present invention~~ may be produced by the methods hereinbelow described.

Page 66, first paragraph, please amend as follows:

The compounds of the present invention may be used as pharmaceuticals or pharmaceutical compositions. More particularly, they may be used as pharmaceuticals useful for therapy or prophylaxis of urinary frequency, urinary urgency or urinary incontinence. Particularly, the compounds may be used for the therapy or prophylaxis of urinary dysfunction such as urinary frequency and urinary incontinence caused by the diseases such as neurogenic bladder, nocturia, overactive bladder, unstable bladder, pollakisuria nervosa, psychogenic frequency, idiopathic frequency, enuresis, cystospasm, chronic cystitis,, interstitial cystitis, chronic prostatitis, benign prostatic enlargement and prostate carcinoma. The term “neurogenic bladder” means that the function of urinary storage or voiding of the lower urinary tract is an abnormal state because of some damage of the nerve innervating the lower urinary tract comprising bladder, urethra and external urinary sphincter. Examples of the diseases which damage the nerve include cerebrovascular disease, brain tumor, brain injury, encephalitis, brain tumor, normal pressure hydrocephalus, dementia, Parkinson’s disease, depression, striato-nigral degeneration, progressive supranuclear palsy, olivo-ponto-cerebellar atrophy, Shy-Drager syndrome, spinal cord injury, vascular disease of spinal cord, spinal cord tumor, myelitis, cervical cord compression disorder, syringomyelia, multiple sclerosis, spina bifida, myelomeningocele, spinal canal stenosis, Tethered cord syndrome, myelopathy, diabetes and pelvic cavity surgery. However, use of the therapeutic or prophylactic agent for urinary frequency or urinary incontinence according to the present invention is not restricted to these diseases.

Page 67, first paragraph, please amend as follows:

The effects of the morphinan derivatives having a nitrogen-containing heterocyclic group represented by Formula (I) may be confirmed by the method described in Brain. Res., vol. 297,

191(1984), or J. Pharmacol. Exp. Ther., vol. 240, 978(1987)998 (1987), but the testing method is not restricted thereto.

Page 67, second paragraph bridging page 68, please amend as follows:

When using the therapeutic or prophylactic agent for urinary frequency or urinary incontinence ~~according to the present invention~~ as a pharmaceutical, the pharmaceutical may be the free base or a salt thereof alone, or the pharmaceutical may optionally be admixed with one or more additives such as vehicles, stabilizers, preservatives, buffering agents, solubilizers, emulsifiers, diluents and isotonic agents. The administration form include formulations for oral administration such as tablets, capsules, granules, powders and syrups; formulations for parenteral administration such as injection solutions, suppositories and liquids; and formulations for topical administration such as ointments, creams and patches. The therapeutic or prophylactic agent for urinary frequency or urinary incontinence ~~according to the present invention~~ may preferably contains the above-described effective ingredient in an amount of 0.01 to 90% by weight, more preferably 0.1 to 70% by weight. Although the administration dose may be appropriately selected depending on the symptom, age, body weight, and administration method and the like, the dose of the effective component per adult per day may be 0.1 μ g to 10 g, preferably 1 μ g to 1 g, more preferably 10 μ g to 100 mg, and may be administered in one time or dividedly in several times.

Page 68, first paragraph, please amend as follows:

The compounds of Formula (I) ~~according to the present invention~~ or salts thereof may be used in combination with one or more other therapeutic or prophylactic agents for urinary frequency or urinary incontinence or with one or more therapeutic or prophylactic agents for diseases which cause a urinary dysfunction (e.g., benign prostatic hyperplasia,, prostate carcinoma, diabetes,

cerebrovascular disease, dementia including Alzheimer's disease, depression, Parkinson's disease and multiple sclerosis).

Page 70, third paragraph, please amend as follows:

Examples

~~The present invention will now be described in detail by way of examples thereof.~~

Page 203, first paragraph, please amend as follows:

From the above, it was proved that the compounds ~~according to the present invention~~ have excellent therapeutic or prophylactic effects against urinary frequency or urinary incontinence.

Page 203, second paragraph, please amend as follows:

The compounds ~~according to the present invention~~ are useful as novel therapeutic or prophylactic agents for urinary frequency or urinary incontinence, from which side effects are diminished.